Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02580747|
Recruitment Status : Unknown
Verified October 2015 by Han weidong, Chinese PLA General Hospital.
Recruitment status was: Recruiting
First Posted : October 20, 2015
Last Update Posted : October 20, 2015
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.
|Condition or disease||Intervention/treatment||Phase|
|Malignant Mesothelioma Pancreatic Cancer Ovarian Tumor Triple Negative Breast Cancer Endometrial Cancer Other Mesothelin Positive Tumors||Biological: anti-meso-CAR vector transduced T cells||Phase 1|
I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-meso vector (referred to as CART-meso cells).
II. Determine duration of in vivo survival of CART-meso cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect and quantify survival of CART-meso TCR (T-cell receptor) zeta:CD137 over time.
I. For patients with detectable disease, measure anti-tumor response due to CART-meso cell infusions.
II. Estimate relative trafficking of CART-meso cells to tumor in bone marrow and lymph nodes.
III. For patients with stored or accessible tumor cells determine tumor cell killing by CART-meso cells in vitro.
IV. Determine if cellular or humoral host immunity develops against the murine anti-meso, and assess correlation with loss of detectable CART-meso (loss of engraftment).
V. Determine the relative subsets of CART-meso T cells (Tcm, Tem, and Treg).
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies|
|Study Start Date :||October 2015|
|Estimated Primary Completion Date :||November 2017|
|Estimated Study Completion Date :||November 2018|
Experimental: anti-meso CAR T cells
Dose escalation will occur using a standard 3+3 dose escalation approach, beginning in dose level I with dose cohorts and rules for escalation and de-escalation.
Patients receive anti-meso-CAR retroviral vector-transduced autologous-derived T cells on days 0, 1, 2 in the absence of disease progression or unacceptable toxicity.
Biological: anti-meso-CAR vector transduced T cells
genetically engineered lymphocyte therapy
Other Name: genetically engineered lymphocyte therapy
- Occurrence of Study related adverse events [ Time Frame: Until week 24 ]defined as >= Grade 3 signs/symptoms, laboratory toxicities, and clinical
- Anti-tumor responses to CART-meso cell infusions [ Time Frame: up to 24 weeks ]
- In vivo existence of CART-meso [ Time Frame: 1 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 70 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Chemotherapy refractory or relapsed mesothelin positive malignant mesothelioma,ovarian tumors,pancreatic cancer,triple negative breast cancer,endometrial cancer and other mesothelin positive tumor
- Patients must be 18 years of age or older.
- Patients must have an ECOG (Eastern Cooperative Oncology Group )performance status of 0-2.
Patients must have evidence of adequate bone marrow reserve, hepatic and renal function as evidenced by the following laboratory parameters:
Absolute neutrophil count greater than 1500/mm3. Platelet count greater than 100,000/mm3. Hemoglobin greater than 10g/dl (patients may receive transfusions to meet this parameter).
Total bilirubin < 1.5 times upper limits of normal. Serum creatinine less than or equal to 1.6 mg/ml or the creatinine clearance must be greater than 70 ml/min/1.73m.
- Seronegative for HIV antibody.
- Seronegative for active hepatitis B, and seronegative for hepatitis C antibody.
- Patients must be willing to practice birth control during and for four months following treatment. NOTE: women of child-bearing age must have evidence of negative pregnancy test.
- Patients must be willing to sign an informed consent.
- Patients with life expectancy less than 12 months will be excluded.
- Patients with uncontrolled hypertension (> 160/95), unstable coronary disease evidenced by uncontrolled arrhythmias, unstable angina, decompensated congestive heart failure (> New York Heart Association Class II), or myocardial infarction within 6 months of study will be excluded.
- Patients with any of the following pulmonary function abnormalities will be excluded: FEV(forced expiratory volume), < 30% predicted; DLCO (diffusing capacity of lung for carbon monoxide) < 30% predicted (post-bronchodilator); Oxygen Saturation less than 90% on room air.
- Patients with severe liver and kidney dysfunction or consciousness disorders will be excluded.
- Pregnant and/or lactating women will be excluded.
- Patients with active infections, including HIV, will be excluded, due to unknown effects of the vaccine on lymphoid precursors.
- Patients with any type of primary immunodeficiencies will be excluded from the study.
- Patients requiring corticosteroids (other than inhaled) will be excluded.
- Patients with history of T cell tumors will be excluded.
- Patients who are participating or participated any other clinical trials in latest 30 days will be excluded.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02580747
|Contact: Weidong Han, Dr.||email@example.com|
|Contact: Yao Wang, Dr.||firstname.lastname@example.org|
|Biotherapeutic Department and Pediatrics Department of Chinese PLA General Hospital||Recruiting|
|Beijing, Beijing, China, 100853|
|Contact: Weidong Han, Dr. 86-10-66937463 email@example.com|
|Contact: Yao Wang, Dr. 86-10-66937376 firstname.lastname@example.org|
|Sub-Investigator: Yao Wang, Dr.|
|Responsible Party:||Han weidong, PI, Chinese PLA General Hospital|
|Other Study ID Numbers:||
|First Posted:||October 20, 2015 Key Record Dates|
|Last Update Posted:||October 20, 2015|
|Last Verified:||October 2015|
Triple Negative Breast Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Neoplasms, Female
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Respiratory Tract Neoplasms